Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Therapies02:49

Cancer Therapies

7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

630
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
630
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

7.7K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pan-cancer analysis reveals Rho kinase addiction as a vulnerability of de-differentiated cancer cells.

iScience·2026
Same author

Nucleophagy removes cytotoxic trapped PARP1.

Nature cell biology·2026
Same author

Two decades of PARP inhibitor synthetic lethality in cancer.

Nature·2026
Same author

Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary Analysis of a Nonrandomized Clinical Trial.

JAMA oncology·2026
Same author

Tumour specific HORMAD1 expression perturbs mitotic arrest and drives sensitivity to mitotic kinase inhibitors.

Nature communications·2026
Same author

An antibody-drug conjugate designed through clone and isotype selection restricts the growth of CSPG4-expressing triple-negative breast cancer.

NPJ precision oncology·2026
Same journal

Palliative Therapy for Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Ablative Therapies for Liver Tumors.

Hematology/oncology clinics of North America·2026
Same journal

Pathology of Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery for Liver and Biliary Tract Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Surgical Considerations for Primary Liver Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Systemic Therapy for Biliary and Liver Neoplasms: Chemotherapy and Immunotherapy.

Hematology/oncology clinics of North America·2026
See all related articles

Related Experiment Video

Updated: Aug 19, 2025

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

2.8K

Systemic Therapy for Hereditary Breast Cancers.

Elizabeth J Harvey-Jones1, Christopher J Lord2, Andrew N J Tutt3

  • 1The Breast Cancer Now Research Unit, Guy's Hospital Cancer Centre, SE1 9RT, United Kingdom; The City of London Cancer Research UK Centre at Kings College London, SE1 9RT, United Kingdom.

Hematology/Oncology Clinics of North America
|November 26, 2022
PubMed
Summary
This summary is machine-generated.

Hereditary breast cancers, often linked to BRCA1/2 gene mutations, are treated with chemotherapy and PARP inhibitors. Research explores new DNA repair inhibitors and immunotherapies to overcome drug resistance and personalize treatment.

Keywords:
BiomarkersChemotherapyDrug resistanceHereditary breast cancerPARPi

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.3K
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

6.8K

Related Experiment Videos

Last Updated: Aug 19, 2025

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

2.8K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.3K
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

6.8K

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Hereditary breast cancers account for 5-10% of all breast cancer cases.
  • Pathogenic variants in homologous recombination genes, such as BRCA1 and BRCA2, are frequently implicated.
  • Understanding genetic predispositions is crucial for effective treatment strategies.

Purpose of the Study:

  • To review current and emerging systemic treatments for hereditary breast cancer.
  • To discuss the mechanisms and management of drug resistance.
  • To highlight the role of biomarker-adapted treatment in future patient care.

Main Methods:

  • Review of approved chemotherapeutic agents.
  • Analysis of targeted therapies, including poly-(ADP ribose) polymerase (PARP) inhibitors.
  • Exploration of novel experimental treatments like small molecule DNA repair inhibitors and immunomodulatory agents.

Main Results:

  • Established treatments include chemotherapy and PARP inhibitors for BRCA-mutated breast cancers.
  • Emerging therapies show promise in preclinical and early clinical studies.
  • Drug resistance mechanisms are being elucidated, with strategies for prevention and delay under investigation.

Conclusions:

  • Systemic therapies, including chemotherapy and PARP inhibitors, are mainstays for hereditary breast cancer.
  • Novel agents and biomarker-driven approaches are essential for improving outcomes and overcoming resistance.
  • Personalized, biomarker-adapted treatment strategies are critical for the future management of hereditary breast cancer.